on Behavioral Health calls. D. 705.18 Dr. Tilles is concerned that charcoal is being given to patients with altered level of conc. causing possible aspiration. He would like to add language to the policy stating that patients with ALOC and/or a short ride to the hospital do not require charcoal.
Dr. Tilles will work on making these changes and present the draft to PSC next month. Agency Reports A.
Fire departments OFD -Stephanie reported that they have a large group in the academy and everything is going well. VCFD -Dede is getting geared up for CAM. SPFD -Had 125 at Sidewalk CPR program during "Ready Santa Paula" B.
Ambulance Providers nothing C.
Base Hospitals LRRMC -Debbie stated that LRRMC would like to volunteer to coordinate a countywide calendar of Sidewalk CPR events. They would also be willing to do all the press associated with the events. SVH -Jennie thanked everyone for their patience with the construction at their facility. There will be an 8 hr CE day in Nov. and at Sta. 43 in Oct. SJRMC -Kathy reported construction in the lobby of their facility. 
RS RS
Agency LastName FirstName 1/10/ 2013 2/14/2013 3/14/2013 4/11/2013 5/9/2013 6/13/2013 7/11/2013 8/8/2013 9/12/2013 10/10/2013 11/14/2013 12/12 Oral ACE inhibitors reduce fatal and nonfatal major cardiovascular events in patients with STEMI (360, 361, 420, 422, [428] [429] [430] . Their protective effects have been demonstrated independent of the use of other pharmacotherapies (i.e., fibrinolytics, aspirin, and beta blockers). The magnitude of clinical benefit is greatest in high-risk patient subgroups (i.e., anterior MI, EF Յ0.40, HF, prior MI, and tachycardia) (431). Demonstration of an early benefit (within the first 24 hours) supports the prompt use of Vol. 61, No. 4, 2013 O'Gara et al. January 29, 2013 2013 ACCF/AHA STEMI Guideline: Full Text these agents in patients without existing contraindications (hypotension, shock, bilateral renal artery stenosis or history of worsening of renal function with ACE inhibitor/ARB exposure, renal failure, or drug allergy). The role of routine long-term ACE inhibitor therapy in low-risk patients after STEMI who have been revascularized and treated with aggressive lipid-lowering therapies is less certain (432). ARBs are indicated for ACE inhibitor-intolerant patients. Specifically, valsartan was found to be noninferior to captopril in the VALIANT (Valsartan in Acute Myocardial Infarction) trial (424). The EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival) study established the benefit of an aldosterone antagonist, eplerenone, added to optimal medical therapy in eligible patients (creatinine Յ2.5 mg/dL in men and Յ2.0 mg/dL in women, potassium Յ5.0 mEq/L) 3 to 14 days after STEMI with EF Յ0.40 and either symptomatic HF or diabetes mellitus (426). A post hoc analysis of the EPHESUS trial suggested a time-dependent treatment effect of eplerenone. Earlier initiation of the drug (Ͻ7 days) significantly reduced the rates of all-cause mortality, sudden cardiac death (SCD), and cardiovascular mortality/hospitalization, whereas initiation Ն7 days had no significant effect on outcomes (433). 
Lipid Management: Recommendations

Nitrates
Although nitroglycerin can ameliorate symptoms and signs of myocardial ischemia by reducing LV preload and increasing coronary blood flow, it generally does not attenuate the myocardial injury associated with epicardial coronary artery occlusion unless vasospasm plays a significant role. Intravenous nitroglycerin may be useful to treat patients with STEMI and hypertension or HF. Nitrates should not be given to patients with hypotension, marked bradycardia or tachycardia, RV infarction, or 5=phosphodiesterase inhibitor use within the previous 24 to 48 hours (444). There is no role for the routine use of oral nitrates in the convalescent phase of STEMI.
Calcium Channel Blockers
An overview of 28 RCTs involving 19,000 patients demonstrated no beneficial effect on infarct size or the rate of reinfarction when calcium channel blocker therapy was initiated during either the acute or convalescent phase of STEMI (445). Calcium channel blockers may be useful, however, to relieve ischemia, lower BP, or control the ventricular response rate to atrial fibrillation (AF) in patients who are intolerant of beta blockers. Caution is advised in patients with LV systolic dysfunction. The use of the immediate-release nifedipine is contraindicated in patients with STEMI because of hypotension and reflex sympathetic activation with tachycardia (446).
Oxygen
Few data exist to support or refute the value of the routine use of oxygen in the acute phase of STEMI, and more research is needed. A pooled Cochrane analysis of 3 trials showed a 3-fold higher risk of death for patients with confirmed acute MI treated with oxygen than for patients with acute MI managed on room air. Oxygen therapy is appropriate for patients who are hypoxemic (oxygen saturation Ͻ90%) and may have a salutary placebo effect in others. Supplementary oxygen may, however, increase coronary vascular resistance (447). Oxygen should be administered with caution to patients with chronic obstructive pulmonary disease and carbon dioxide retention. "The fatality occurred in a 47 year old white man who complained of exertional dyspnea for nine years and intermittent claudication for three years. There was no history of angina pectoris, chest pain, or congestive heart failure. His cardiac examination was entirely normal with the exception of the electrocardiogram which showed a normal QRS loop but an abnormally directed T vector, producing inverted T waves in Leads I and Va to Vg. One hour following the oral administration of 15.0 Gms. of potassium chloride the patient developed short runs of ventricular tachycardia at a time when there were only slight potassium effects as evidenced by increase in T-vector magnitude. Eighty minutes following potassium administration the patient developed fatal ventricular fibrillation. Just prior to the onset of the ventricular fibrillation the T vector was still only slightly increased in magnitude with no change in direction. None of the other electrocardiogram signs of potassium intoxication appeared, such as P-R interval abnormalities, absence of P waves, or intraventrirular block. Post-mortem examination revealed a marked degree of coronary artery sclerosis with many focal areas of myocardial fibrosis, but no area of frank myocardial infarction." 
Narcan -it is not necessary that the patient be awake and alert. Administer until max dosage is reached or RR greater than 12/min. When given to chronic opioid patients, withdrawal symptoms may present. IM dosing is the preferred route of administration. 
